Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockFollistatin
Third-Party TestedPurity Standards
Total
$99.99Size
Quantity
1
Bundle & Save
Molecular Profile
Molecular Profile
Type
Secreted glycoprotein (follistatin family; TGF-β-superfamily ligand trap)
Molecular weight
~38,007 g/mol (FST-344 precursor; UniProt P19883)
Amino acids
344
Modification
Single-chain, cysteine-rich, N-glycosylated protein organized as an N-terminal domain followed by three follistatin domains (FSD1-FSD3), each built from an EGF-like and a Kazal-like subdomain; a basic heparin-binding sequence lies within FSD1. Alternative splicing of the FST gene yields the FST-344 precursor (processed to the circulating FST-315 form) and the FST-288 isoform; FST-288 exposes the heparin-binding sequence and associates with cell-surface heparan sulfate, whereas the acidic C-terminal extension of FST-315 masks it.
Mechanism & Target Class
Mechanism & Target Class
Follistatin functions as an extracellular ligand trap for TGF-β-superfamily ligands. Two follistatin molecules encircle a single ligand dimer (activin A/B, myostatin/GDF-8, GDF-11, and several BMPs), with the N-terminal domain occupying a type I receptor-like site and FSD1-FSD2 occluding the type II receptor site, forming a non-signaling complex. Sequestration prevents the ligands from engaging activin type II receptors (ActRIIA/ActRIIB) and the downstream SMAD2/3 pathway. The isoform-specific acidic C-terminal extension modulates exposure of the heparin-binding sequence and thereby cell-surface (heparan-sulfate) association.
Storage & Handling
Storage & Handling
Lyophilized
20°C to -80°C, desiccated
General handling context for a cysteine-rich glycoprotein, not a product-specific protocol; aliquot, keep sealed, and protect from repeated freeze-thaw.
References
References
Reviews
- 1
Lee SJ. (2023). Annu Rev Physiol
- 2
Cash JN, Angerman EB, Keutmann HT, Thompson TB. (2012). Mol Endocrinol
Clinical
- 3
Mendell JR, et al. (2017). Mol Ther
- 4
Greenberg SA. (2017). Mol Ther
- 5
Mendell JR, et al. (2015). Mol Ther
- 6
ClinicalTrials.gov. ClinicalTrials.gov
Primary research
- 7
Pearsall RS, et al. (2019). Skeletal Muscle
- 8
Shen X, et al. (2019). Sci Rep
- 9
Cash JN, Rejon CA, McPherron AC, Bernard DJ, Thompson TB. (2009). EMBO J
- 10
Kota J, et al. (2009). Sci Transl Med
- 11
Haidet AM, et al. (2008). PNAS
- 12
Lee SJ. (2007). PLoS ONE
- 13
Lerch TF, Shimasaki S, Woodruff TK, Jardetzky TS. (2007). J Biol Chem
- 14
Harrington AE, et al. (2006). EMBO J
- 15
Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS. (2005). Dev Cell
- 16
Lee SJ, McPherron AC. (2001). PNAS
- 17
Tsuchida K, et al. (2000). J Biol Chem
- 18
Matzuk MM, Lu N, Vogel H, Sellheyer K, Roop DR, Bradley A. (1995). Nature
- 19
Nakamura T, et al. (1990). Science
- 20
Shimasaki S, Koga M, Esch F, et al. (1988). PNAS
- 21
Ueno N, Ling N, Ying SY, Esch F, Shimasaki S, Guillemin R. (1987). PNAS
Primary Database
Primary Database
Also known as: FST-344 (full-length precursor), FST-315 (mature circulating form), FST-288 (tissue-bound isoform)
View this compound in the Research Library →Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
